Ventracor (ASX: VCR) Announce 150 VentrAssist Implants Worldwide
Ventracor (ASX: VCR) today announced the 150th implant of the VentrAssist Left Ventricular Assist Device (LVAD).
Ventracor (ASX: VCR) today announced the 150th implant of the VentrAssist Left Ventricular Assist Device (LVAD).
Ventracor (ASX: VCR) today announced its results for the year ending 30 June 2007, with increasing sales revenues in the US, Europe and Australasia of $4.9m (2006;$1.1m) from 64 implants, and a net loss of $36.5m (2006;$30m).
Following significant shareholder enquiry, the Company provides an update of the status of the international clinical trial currently underway for HeartWare's (ASX: HTW) HVAD TM Left Ventricular Assist Device.
Ellex Medical Lasers Limited (ASX: ELX) - Raises $5.5 million through Placement - Mr Peter Falzon, CEO; Boardroomradio is pleased to announce that Ellex Medical Lasers Limited (ASX: ELX) has published an audio file.
Ventracor (ASX: VCR)(ADR: VTCRY) today announced the first patient implant in the US Bridge to Transplant (BTT) pivotal trial of the VentrAssist(tm) left ventricular assist device (LVAD) at the Medical University of Minnesota, in Minneapolis.
Ventracor (ASX: VCR)(ADR: VTCRY) yesterday confirmed growing momentum in Europe and the USA, with increases in the number of VentrAssist(tm) Left Ventricular Assist Device (LVAD) implants, resulting in record monthly sales revenue.
Ventracor (ASX: VCR) (ADR: VTCRY) is about to commence two major clinical trials in the US after the company successfully completed a Feasibility Trial. The first is a Bridge to Transplant (BTT) Pivotal Trial for patients on the transplant list; the FDA recently approved the start of this trial.